A phase Ib, multicenter trial evaluated whether the combination of T-DXd (DS-8201, a HER2-targeted ADC) and pembrolizumab in NSCLC patients was safe, tolerable and preliminarily effective [185]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.